NCT02681809 - A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

November 18, 2019

Study Completion Date

November 18, 2019

Conditions

Diabetic RetinopathyPosterior Vitreous DetachmentDisease Progression

Interventions

DRUG

ocriplasmin 0.0625mg

Up to 3 intravitreal injections of ocriplasmin 0.0625mg approximately 1 month apart

DRUG

ocriplasmin 0.125mg

Up to 3 intravitreal injections of ocriplasmin 0.125mg approximately 1 month apart

DRUG

Sham injection

3 sham injections approximately 1 month apart. No actual injections. No medication is used.

Trial Locations (38)

1062

Budapest

1083

Budapest

1106

Budapest

1133

Budapest

4032

Debrecen

8025

Barcelona

9700

Szombathely

17007

Girona

20132

Milan

22903

Charlottesville

47012

Valladolid

57701

Rapid City

64297

Darmstadt

75475

Paris

78240

San Antonio

78503

McAllen

80336

München

84101

Beersheba

85021

Phoenix

92354

Loma Linda

92697

Irvine

92705

Santa Ana

95008

Campbell

4941492

Petah Tikva

6423906

Tel Aviv

7610001

Rehovot

625 00

Brno

500 05

Hradec Králové

779 00

Olomouc

530 02

Pardubice

100 34

Prague

140 00

Prague

760 01

Zlín

04103

Leipzig

08195

Barcelona

GU16 7UJ

Frimley

EC1V 2PD

London

SE5 9RS

London